We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In In re ’318 Patent Infringement Litigation, Nos. 08-1594, 09-1070, -1088 (Fed. Cir. Sept. 25, 2009), the Federal Circuit affirmed the district court’s judgment against Janssen Pharmaceutica N.V., Janssen L.P., and Synaptech, Inc. (collectively “Janssen”), holding that the claims of U.S. Patent No. 4,663,318 (“the ’318 patent”) were invalid for lack of enablement
